We obtain the fair values of our Level 2 financial instruments, which are not in active markets, from a primary professional pricing source that uses quoted market prices for identical or comparable instruments, rather than direct observations of quoted prices in active markets. Fair values obtained from this professional pricing source can also be based on pricing models whereby all significant observable inputs, including maturity dates, issue dates, settlement dates, benchmark yields, reported trades, broker-dealer quotes, issue spreads, benchmark securities, bids, offers or other market related data, are observable or can be derived from, or corroborated by, observable market data for substantially the full term of the asset.

We estimate the fair values of our Level 3 financial instruments based on unobservable inputs and other estimation techniques due to the absence of quoted market prices and inherent lack of liquidity.

The following table summarizes financial assets that we measured at fair value on a recurring basis as of September 30, 2026, classified in accordance with the fair value hierarchy:



	Fair Value Measurements Using
(In millions)	Level 1		Level 2		Level 3		Total
Cash equivalents	$	402.3	$	5.5	$	—	$	407.8

Debt securities, available-for-sale:
U.S. government agencies (1)	—		336.0		—		336.0
Commercial paper	—		132.6		—		132.6
Corporate debt	—		387.9		—		387.9

Total debt securities, available-for-sale	—		856.5		—		856.5

Other assets:
Convertible note investments	—		—		10.7		10.7
Deferred compensation plan assets (2)	21.8		—		—		21.8


Total assets measured at fair value on a recurring basis	$	424.1	$	862.0	$	10.7	$	1,296.8

The following table summarizes financial assets that we measured at fair value on a recurring basis as of December 31, 2025, classified in accordance with the fair value hierarchy:


	Fair Value Measurements Using
(In millions)	Level 1		Level 2		Level 3		Total
Cash equivalents	$	392.8	$	—	$	—	$	392.8

Debt securities, available-for-sale:
U.S. government agencies (1)	—		357.3		—		357.3
Commercial paper	—		123.4		—		123.4
Corporate debt	—		600.3		—		600.3

Total debt securities, available-for-sale	—		1,081.0		—		1,081.0

Other assets:
Convertible note investments	—		—		10.5		10.5
Deferred compensation plan assets (2)	20.0		—		—		20.0

Total assets measured at fair value on a recurring basis	$	412.8	$	1,081.0	$	10.5	$	1,504.3

As we conduct business globally in many currencies, we are exposed to foreign exchange rate changes. To limit this exposure, we enter into foreign currency forward contracts to hedge monetary assets and liabilities, including intercompany loans, denominated in non-functional currencies. Our foreign currency forward contracts are not designated as hedging instruments. Therefore, changes in the fair values of these contracts are recognized in other income, net in our condensed consolidated statements of operations, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The duration of these contracts are generally less than one year.

As of September 30, 2026 and December 31, 2025, the notional amounts of outstanding foreign currency forward contracts were $273.3 million and $229.3 million, respectively. The resulting impact on our condensed consolidated financial statements from currency hedging activities was not significant for the three and nine months ended September 30, 2026 and September 30, 2025.

We monitor the costs and the impact of foreign currency risks upon our financial results as part of our risk management program. We do not use derivative financial instruments for speculation or trading purposes or for activities other than risk management. We do not require and are not required to pledge collateral for these financial instruments and we do not carry any master netting arrangements to mitigate the credit risk.

In accordance with authoritative guidance, we measure certain non-financial assets and liabilities at fair value on a non-recurring basis. These measurements are usually performed using the discounted cash flow method or cost method and Level 3 inputs. These include items such as non-financial assets and liabilities initially measured at fair value in a business combination and non-financial long-lived assets measured at fair value for an impairment assessment. In general, non-financial assets, including goodwill, intangible assets, and property and equipment, are measured at fair value when there are indicators of impairment and are recorded at fair value only when an impairment is recognized.

Our non-marketable equity investments without readily determinable fair values are accounted for under the measurement alternative. As such, we measure these investments at cost less impairment, adjusted for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. It is impracticable for us to estimate the fair value of these investments on a recurring basis due to the fact that these entities are privately held and limited information is available. We include the carrying values of these investments in other assets in our condensed consolidated balance sheets. Adjustments to the carrying values of these investments as a result of observable price changes and impairments are recorded in other income, net in our condensed consolidated statements of operations.

The carrying values of our non-marketable equity investments were $217.5 million as of September 30, 2026 and $218.0 million as of December 31, 2025. During the three and nine months ended September 30, 2026, we did not record any upward adjustments. During the three and nine months ended September 30, 2025, we recorded upward adjustments of $82.5 million for observable price changes.

For our non-marketable equity investments held as of September 30, 2026, the cumulative upward adjustments for observable price changes were $82.5 million and cumulative downward adjustments and impairments were not significant.

During the three and nine months ended September 30, 2026, net unrealized losses on non-marketable equity investments were not significant. During the three and nine months ended September 30, 2025, net unrealized gains on non-marketable equity investments were $82.5 million and $80.0 million, respectively.

There were no significant impairment losses on assets and liabilities measured at fair value on a non-recurring basis during the three and nine months ended September 30, 2026 and September 30, 2025.